ACET today
$2.99-$0.01 (-0.33%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourBullish
1 hourLeaning Bearish
15 minSymmetric Triangle
5 minExpanding
Daily trend turns up above $9.97
Key levels
Resistance$6.42
Resistance$6.05
Support$2.87
Latest news & SEC filings
AnalystGuggenheim keeps Buy rating on Adicet Bio, cuts price target to $55
EarningsAdicet Bio posts Q3 2026 results, issues business update
EarningsAdicet Bio posts wider quarterly loss than analysts expected
ProductAdicet Bio sets Q1 2027 timing for prula-cel lupus data and FDA news
All ACET news →About Adicet Bio
Adicet Bio develops donor-derived gamma delta T cell treatments intended for use without patient matching, aimed at autoimmune conditions and tumors. Its main candidate, prula-cel, carries a chimeric antigen receptor aimed at CD20 and is being tested in early human studies for lupus-related kidney disease, lupus, systemic sclerosis and other autoimmune disorders. A second program, ADI-212, targets prostate cancer. The company is based in the United States.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Adicet Bio, Inc. (ACET)
What Is the Price Target for ACET?
SEPT Low Target
$27.00
SEPT Mid Target
$27.50
SEPT High Target
$28.00
Analyst Consensus
$27.50
Is ACET a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ACET.
Start Free Trial →Is ACET Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$26.49
12
Moat Score
NONE
1/9
Piotroski Score
-5.3
Altman Z-Score
What Is Smart Money Doing with ACET?
Insider Signal
SELLING
3 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ACET Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
20.53%
FCF Growth YoY
-3.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for ACET
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ACET, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:58:22 | $3.00 | 1,641 | $$5K | MIDPOINT |
| 20:57:06 | $2.95 | 2,558 | $$8K | SELL |
| 20:46:54 | $2.99 | 1,500 | $$4K | SELL |
| 20:36:25 | $3.00 | 2,822 | $$8K | BUY |
| 20:23:04 | $2.95 | 6,000 | $$18K | BUY |
5 dark pool trades shown · $$43K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Adicet Bio, Inc. (ACET) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ACET — frequently asked questions
What is ACET stock price today?
Adicet Bio, Inc. (ACET) is at $2.99, down 0.33% (-$0.01) at the Nov 11, 2026 close.
Why is ACET stock moving today?
Latest ACET news — Nov 6, 2026: Guggenheim keeps Buy rating on Adicet Bio, cuts price target to $55 · Nov 6, 2026: Adicet Bio posts Q3 2026 results, issues business update
What is the ACET price target?
The average analyst price target for ACET is $27.50, ranging from $27 to $28, based on 2 analysts. Latest: Wedbush maintains on Sep 29, 2026.
What do analysts rate ACET?
Analyst ratings for ACET: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did ACET beat earnings?
ACET last reported on Nov 5, 2026: EPS -$1.76 vs -$1.59 expected — a miss of 10.7%.
Does ACET pay a dividend?
ACET does not currently pay a dividend.
What are ACET support and resistance levels?
Support: $2.87. Resistance: $6.05, $6.42, $7.02.
What are insiders doing with ACET?
Insider activity: SELLING, 3 buys and 4 sells in the last 90 days.
What is the latest news on ACET?
Nov 6, 2026: Guggenheim keeps Buy rating on Adicet Bio, cuts price target to $55 · Nov 6, 2026: Adicet Bio posts Q3 2026 results, issues business update · Nov 5, 2026: Adicet Bio posts wider quarterly loss than analysts expected